Abstracts tagged "appropriateness"

Abstract Number: 278 • 2018 ACR/ARHP Annual Meeting
The Effect of Patient, Prescriber and Region on the Initiation of First Biologic for Rheumatoid Arthritis: A Longitudinal Population Study
Mark Tatangelo¹, George A. Tomlinson², Michael Paterson³, Nick Bansback⁴, Tara Gomes¹, Alex Kopp³, Vandana Ahluwalia⁵ and Claire Bombardier⁶, ¹University of Toronto, Toronto, ON, Canada, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴St Paul's Hospital, Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ⁵Ontario Rheumatology Association, Brampton, ON, Canada, ⁶Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Prescribing the first biologic for rheumatoid arthritis is an important decision for physicians, payers, and patients with costs and clinical implications. Our aim was…
Abstract Number: 440 • 2018 ACR/ARHP Annual Meeting
Assessing Inappropriate Pain Management in Adults with Hip or Knee Osteoarthritis Treated with Different Opioid Intensity Regimens: Results from a Retrospective Database Analysis
Nathaniel P. Katz^1,2, Kavita Gandhi³, Wenhui Wei⁴, Ahong Huang⁵ and Li Wang⁶, ¹President, Analgesic Solutions, Natick, MA, ²Tufts University School of Medicine, Boston, MA, ³Director, Global Health Economics and Outcomes Research, Teva Pharmaceutical Industries, Frazer, PA, ⁴Senior Director, Health Economics and Outcomes Research (HEOR), Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Project Manager, STATinMED Research, Dallas, TX, ⁶Senior Director, Analytic Research, STATinMED Research, Dallas, TX
Background/Purpose: Opioids are often prescribed for osteoarthritis (OA) pain management despite the need for balancing their risks and benefits. Since there are no standard criteria…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].